Nephrocare Health IPO listing: Shares make modest debut with nearly 7% premium
Nephrocare Health shares debut on stock markets at nearly 7% premium, listing at ₹490 on NSE and ₹491 on BSE after its IPO.
Nephrocare Health makes a steady stock market debut with shares listing at a premium on NSE and BSE.
Nephrocare Health shares made a moderate debut on the Indian stock market on Wednesday, December 17, listing at a premium of nearly 7% over the issue price. The stock opened at ₹490 on the NSE and ₹491 on the BSE, translating into a gain of 6.89% for IPO allottees against the upper price band of ₹460.
Ahead of the listing, Nephrocare Health shares were trading at a grey market premium (GMP) of around ₹37, indicating positive but cautious sentiment among investors prior to the debut.
Nephrocare Health IPO details
The Nephrocare Health IPO was a book-built issue comprising a mix of fresh issue and offer for sale (OFS). The firm intended to get around ₹871 crore via the public offering from the capital markets.
The IPO had a price range of ₹438 to ₹460 per share along with a lot size of 32 shares. Investors received shares on Monday, December 15, 2025, in advance of the official listing on December 17.
As per the red herring prospectus (RHP), the primary use of the IPO proceeds will be to expand the company's network by setting up new dialysis clinics throughout India. A part of this money will be used to reduce existing debt, while the rest will be reserved for general corporate purposes.
With a steady listing performance, Nephrocare Health’s stock will now be closely watched to see how it performs in the secondary market amid broader investor sentiment.
